Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MkjBSpVv[3Srb36gRZN{[Xl? MXywMlXDqM7:TR?= NHOzcYEzPCCq MlnIe4F1\XJ? MnvycY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> M{nJPVI2OTJ|MEiy
Eca109 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3NE42NzJwNT:1JO69VQ>? NUH1cnhzOjRxNEivO|IhcA>? NUfjSZJ6f2G2ZYK= NFTlW2tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy Mkn6NlUyOjNyOEK=
Eca109 NX\Fcm42TnWwY4Tpc44hSXO|YYm= NHrYOWMxNjYEoN88US=> NXXrc2s3Pi9zMj:yOEBp M{O2WpdifGW{ NF\IWYxqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MmDlNlUyOjNyOEK=
Eca109 MVnGeY5kfGmxbjDBd5NigQ>? MWmwMlXDqM7:TR?= M1L5SVI1KGh? NUXwXJhHf2G2ZYK= NFjsWWJqdmirYnn0d{Bk\WyuIHnueoF{cW:w MWmyOVEzOzB6Mh?=
Eca109 M{XUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiwMlXDqM7:TR?= NInHVZIzPCCq MVT3ZZRmeg>? M4P3NYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MonQNlUyOjNyOEK=
Eca109 M1;Xd2Z2dmO2aX;uJGF{e2G7 M3rRRlAvPS9zIN88US=> NW\jUmo3OjRiaB?= NYX4OG1xf2G2ZYK= MVfk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MX:yOVEzOzB6Mh?=
SW1116  MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVro[4s4OC53L{GvNk82KM7:TR?= NHTte4E1QCCq NHvHN|NFVVOR Ml;r[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NInie2EzPDh5NEK4Oi=>
LOVO MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT4NE42NzFxMj:1JO69VQ>? M4n6Z|Q5KGh? MW\EUXNQ MXXlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NUXPT2hQOjR6N{SyPFY>
SW1116  NHjH[W1HfW6ldHnvckBCe3OjeR?= MYWxNEDPxE1? NVuycpllPDhiaB?= M1LQemROW09? M3m4dolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MlvPNlQ5PzR{OE[=
LOVO MV7GeY5kfGmxbjDBd5NigQ>? M1[xXVExKM7:TR?= MofiOFghcA>? NVjBcVJsTE2VTx?= NFzEVYlqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M4j5b|I1QDd2Mki2
SW1116  NWjWVVhmSXCxcITvd4l{KEG|c3H5 NX\iRYRTOTBizszN M4LzdFQ5KGh? MY\EUXNQ MoDD[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MYiyOFg4PDJ6Nh?=
LOVO NFyycGJCeG:ydH;zbZMhSXO|YYm= NVLEXmc2OTBizszN NXjJV3FpPDhiaB?= NVHtV|RHTE2VTx?= MlXX[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz Ml7jNlQ5PzR{OE[=
RPMI-8226 MUnBdI9xfG:|aYOgRZN{[Xl? MVWxM|Ih|ryP NV7iXIJmPDhxN{KvPVYhcA>? M2jYW2ROW09? NIS0bYpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NU\HWGpIOjR6M{OxNFg>
OPM-2  NYG5XndRSXCxcITvd4l{KEG|c3H5 MVOxM|Ih|ryP MVW3Nk86Pi9zMkCgbC=> NGD0eoZFVVOR NXTVW|h5cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M2TEVVI1QDN|MUC4
JJN3  MlPTRZBweHSxc3nzJGF{e2G7 MknmNE42NzFizszN NHX4bIYzPC92ODDo NUHJeYlHTE2VTx?= M1;5Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXrGcYVZOjR6M{OxNFg>
NCI-H929  NInBfFVCeG:ydH;zbZMhSXO|YYm= MUixM|Ih|ryP NFnVUmM4Oi97Nj:xNlAhcA>? Mly5SG1UVw>? NGjneXlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHnr[FMzPDh|M{GwPC=>
RPMI-8226 M3zNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X3cFEwOiEQvF2= MXiyOE81QC95MjDo M4TobGROW09? MnraZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M2rsXVI1QDN|MUC4
OPM-2  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Kzd|EwOiEQvF2= NXXpSnJXOjRxNEivO|IhcA>? MnzySG1UVw>? NWfheoNJ[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M{S4RlI1QDN|MUC4
JJN3  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTIR2QxOC53L{Gg{txO MoPYNlQwPDhxN{KgbC=> Mme1SG1UVw>? M1XrPYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M3;rflI1QDN|MUC4
NCI-H929  M{T1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDRUXcyNzJizszN MkPONlQwPDhxN{KgbC=> MUDEUXNQ NHfseGZi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NEnWfFIzPDh|M{GwPC=>
HeLa NVHhTY1CU2mwYYPlJGF{e2G7 NWqzeFdXU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NHKwOmgzPDd6MEC5PC=>
HeLa NGPxfHNMcW6jc3WgRZN{[Xl? MXHLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= Mni1NlQ4QDByOUi=
HeLa MnTMT4lv[XOnIFHzd4F6 MYTLbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx NXjtUpN1OjR5OECwPVg>
HeLa NFOyc5ZMcW6jc3WgRZN{[Xl? M2TwR2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NGXJPXEzPDd6MEC5PC=>
NB4 MXnGeY5kfGmxbjDBd5NigQ>? NV3CcWduOi53L{WvO{42NzFyIN88US=> MYOyOEBp NHvI[ppFVVOR MmXwbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MkG3NlQ1QDR6N{C=
CD4+ CD25− T  NVLJW4dTTnWwY4Tpc44hSXO|YYm= MYGxM|Uh|ryP NH3DXlZz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? MoPoNlQ1PzZ|NkC=
BV-173 NIjvSGFCeG:ydH;zbZMhSXO|YYm= NX3pbXBGOC5{NT:wMlUwOC55NT:xJO69VQ>? MkDHOFgwPzJxOU[gbC=> M1vLN:KhWEKV NV3TN2F[cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NXvvfmtMOjR2MkO2NVM>
ML-1 NFLqNXVCeG:ydH;zbZMhSXO|YYm= M1Syc|AvOjVxMD61M|AvPzVxMTFOwG0> MU[0PE84Oi97NjDo NXrhbYUzyqCSQmO= NV7UVnk{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NG\2c2UzPDR{M{[xNy=>
HL-60 M{HCc2Fxd3C2b4Ppd{BCe3OjeR?= NF\HUWkxNjJ3L{CuOU8xNjd3L{Gg{txO MWW0PE84Oi97NjDo NHrmRWHDqFCEUx?= MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MlPMNlQ1OjN4MUO=
KG-1a NGXTemhCeG:ydH;zbZMhSXO|YYm= MXiwMlI2NzBwNT:wMlc2NzFizszN NH[yOZM1QC95Mj:5OkBp Ml33xsBRSlN? MoHYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3jmUlI1PDJ|NkGz
BV-173 MkfpSpVv[3Srb36gRZN{[Xl? NXr0boY4OjVyL{WwNI5O M2PMTFQ5KGh? M3q2WuKhWEKV NIfoZoZqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NH;HPJYzPDR{M{[xNy=>
CEM M4nYbmZ2dmO2aX;uJGF{e2G7 MXWyOVAwPTBybl2= NFX4WGw1QCCq MmjGxsBRSlN? NH;aVVZqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NFLQfIUzPDR{M{[xNy=>
HL-60 MnjWSpVv[3Srb36gRZN{[Xl? NYXCd4xnOjVyL{WwNI5O M1T4e|Q5KGh? MXRCpHBDWw>? NULBb3R4cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NXTxemxpOjR2MkO2NVM>
ML-1 MX7GeY5kfGmxbjDBd5NigQ>? Mn\hNlUxNzVyMH7N MYO0PEBp MUVCpHBDWw>? NGGy[IFqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NFfMfoYzPDR{M{[xNy=>
DLD-1 M4fGcmZ2dmO2aX;uJGF{e2G7 M1O2UlI2OC93MEDuUS=> NWnaVHlIPDhiaB?= M{PIbeKhWEKV M4L3Z4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MVqyOFQzOzZzMx?=
HCT-116 M2\3PWZ2dmO2aX;uJGF{e2G7 MU[yOVAwPTBybl2= NGPSbog1QCCq NHr6TYrDqFCEUx?= MXjkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MYCyOFQzOzZzMx?=
U937-A/E-9/14/18  NHXiOpFCeG:ydH;zbZMhSXO|YYm= MonWNE4xOS9yLkGvNU8yOCEQvF2= MUK0PEBp NHPHfIxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MViyOFMxODR3Nh?=
HT29 NWP5cnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyyfWY4OiCq NWjzcYpsUUN3ME2xOFAxyrFzN{mg{txO MVyyOFE4OjB4MR?=
SW48 NIjHO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HCVFczKGh? MlnsTWM2OD1zNT6yxtE3NjJizszN MVeyOFE4OjB4MR?=
HCT116 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnCPGR5PzJiaB?= MYPJR|UxRTFwN9MxNE41KM7:TR?= MlzqNlQyPzJyNkG=
HepG2 MlHjSpVv[3Srb36gRZN{[Xl? NI\xS|gxNjVxMTFOwG0> NXnxWY93OjRiaB?= NI\INY9FVVOR NXznUlhFfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= M1TaTFI1OTR4OEe0
LS174T M4TCc2Z2dmO2aX;uJGF{e2G7 MYSwMlUwOSEQvF2= MYGyOEBp M2TKb2ROW09? NV;lb|dLdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> MmPTNlQyPDZ6N{S=
HepG2 MUfBdI9xfG:|aYOgRZN{[Xl? MU[xM|ExNzFyMDFOwG0> NYfEOYdZPyCm M4\LUmROW09? NWrVV|hHcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWTrOnZqOjRzNE[4O|Q>
LS174T M2nyW2Fxd3C2b4Ppd{BCe3OjeR?= NEDP[4syNzFyL{GwNEDPxE1? NHnWSZA4KGR? MnXLSG1UVw>? M{\1V4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlvqNlQyPDZ6N{S=
QBC-939 M1nmOGFxd3C2b4Ppd{BCe3OjeR?= MoDvNU8yOC9zMECg{txO MWi3JIQ> MoXNSG1UVw>? NELV[5BqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnjuNlQyPDZ6N{S=
U251 Mmf0RZBweHSxc3nzJGF{e2G7 NX[1SXB2OS9zMD:xNFAh|ryP MWK3JIQ> NUfGeppPTE2VTx?= NFfQeotqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn7VNlQyPDZ6N{S=
HL-60 M3fQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjPbYIyKM7:TR?= NEnvVXc1QCCq MUHpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? NVLLNVBuOjRyMECzNlQ>
MDA‑MB‑453 M{f3bmZ2dmO2aX;uJGF{e2G7 NWLke3JZOC5{L{Gg{txO NWiwd4J1PzJiaB?= MnqzZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NVfVS2kyOjN6NESyNlg>
HCC1569 NFrVTW5HfW6ldHnvckBCe3OjeR?= NV;KSJlWOC5{L{Gg{txO MVK3NkBp MVHjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MluxNlM5PDR{Mki=
BT‑474 NX7mVGZ1TnWwY4Tpc44hSXO|YYm= MVmwMlIwOSEQvF2= MW[3NkBp MW\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MUKyN|g1PDJ{OB?=
AGS MUjBdI9xfG:|aYOgRZN{[Xl? NXTXenQzPS9zMD:yNE82OCEQvF2= M4[ze|Q5yqCqwrC= M4XBW2ROW09? NWjUemhKcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NITTUIQzOzV6Mke4OC=>
A549 MmGxRZBweHSxc3nzJGF{e2G7 MVO1M|ExNzJyL{WwJO69VQ>? NILPfJg1QMLiaNMg NGLQS5lFVVOR M2XEN4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NIrPcnMzOzV6Mke4OC=>
AGS  Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX61M|ExNzJyL{WwJO69VQ>? MmDBOFjDqGkEoB?= MmPoSG1UVw>? NYDMV4g{cW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh M1zpdFI{PTh{N{i0
Kasumi-1 NHv6d2NCeG:ydH;zbZMhSXO|YYm= NFPaSY4xNjVizszN MYO0POKhcMLi M3zSeYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NVrsN|JZOjN2OUOzOFg>
OCI-AML3 M2jVVGFxd3C2b4Ppd{BCe3OjeR?= NVnkSJpHOi53IN88US=> MXu0POKhcMLi MX;k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NGKxWZUzOzR7M{O0PC=>
MV4-11 NYnXNnF3SXCxcITvd4l{KEG|c3H5 NFjuT|YzNjVizszN M4\4N|Q5yqCqwrC= NVHFXJVJ\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NFTVcoUzOzR7M{O0PC=>
NK  M2LmSGN6fG:2b4jpeJkhSXO|YYm= MWKwMlAzNTJyIN88US=> NX\rR2U3PSCm M3LLWYRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? NVq4dogxOjN|MkiwPFg>
NK  MUHBdI9xfG:|aYOgRZN{[Xl? NXPSTFRWOC5yMj2yNEDPxE1? NELjRmQ2KGR? M4PoTYRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? NUS3T4pMOjN|MkiwPFg>
NK  Mn22SpVv[3Srb36gRZN{[Xl? MX2wMlAyNTJyIN88US=> NGD0e3E2KGR? MXvjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NV21bGdmOjN|MkiwPFg>
MOLT4/DNR M1XWNGZ2dmO2aX;uJGF{e2G7 Mk[4OUDPxE1? M1jKc|Qh\A>? NXGzbm5vemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M4TB[FI{ODZyNUew
Jurkat/DOX NWLITno{TnWwY4Tpc44hSXO|YYm= NU\XbmJvPSEQvF2= M4LSXlQh\A>? NHznSIpz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? M3rDe|I{ODZyNUew
MOLT4/DNR NE\LPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnQPYl5PSEQvF2= NWDGeYpqPCCm NYHXdXE1emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NFPPbVIzOzB4MEW3NC=>
Jurkat/DOX MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHwXm1[PSEQvF2= MkGwOEBl NUnJZVdXemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M4DlRVI{ODZyNUew
ccRCC  NXL4eoM2SXCxcITvd4l{KEG|c3H5 MUWwMlAyNTFyzszN NYDTUmUyPzJiaB?= NEKwbY5FVVOR MWXoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NUjoU|lROjJ6Mk[0Olc>
TNBC  MmXERZBweHSxc3nzJGF{e2G7 NGrzdlExNjBzLUGw{txO MVq3NkBp MX3EUXNQ NHPoNYFp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w M4XOdlIzQDJ4NE[3
A498 M4\HeGFxd3C2b4Ppd{BCe3OjeR?= MX[wMlAyNTFyzszN NHX5SGg4OiCq MYDEUXNQ M4X6Zolv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> M1W3NFIzQDJ4NE[3
KIJ265T MlSzRZBweHSxc3nzJGF{e2G7 NWHRcJFiOC5yMT2xNO69VQ>? M1m5SlczKGh? NHfGboZFVVOR NIHEbm5qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NFv3RXMzOjh{NkS2Oy=>
MDA-231 MofhRZBweHSxc3nzJGF{e2G7 M3jUdFAvODFvMUFOwG0> NHXW[oM4OiCq M3K1PWROW09? NIXLWY1qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NFLNPZgzOjh{NkS2Oy=>
BT-20 NVzyN4VzSXCxcITvd4l{KEG|c3H5 M3\2VVAvODFvMUFOwG0> NXr3UGVxPzJiaB?= MYnEUXNQ NHrQfodqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M2ruXlIzQDJ4NE[3
U937 NIH2V45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfpepZ3PS1{MDFOwG0> NYXFSnhFOjRxNEivO|IhcA>? MnvUbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MlLoNlI4PjdyMkG=
HL60 NHP1TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO1MVIxKM7:TR?= MXmyOE81QC95MjDo M1:4cIlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M3LE[VIzPzZ5MEKx
U937 MlHlRZBweHSxc3nzJGF{e2G7 MofnNVUh|ryP MViyOE81QC95MjDo MlPWbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXqyNlc3PzB{MR?=
HL60 Mo\lRZBweHSxc3nzJGF{e2G7 M1jrdFE2KM7:TR?= MnXMNlQwPDhxN{KgbC=> MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHjsc2szOjd4N{CyNS=>
LS411N  NUH1Zpk3SXCxcITvd4l{KEG|c3H5 Mkm4NE42KM7:TR?= NE\zNlg4OiCq NF74[ItqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= M1fwS|IzPDZzNkm1
MDA-MB-231 MlnrRZBweHSxc3nzJGF{e2G7 M4W2fFExKM7:TR?= M3vnbFQ5KGh? MXTy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXrQZ3AyOjF6OEe2PVc>
MCF-7  NGj0SoZCeG:ydH;zbZMhSXO|YYm= M3flcFExKM7:TR?= MUm0PEBp NHqzW2Zz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4H5eFIyQDh5Nkm3
A375 NFTObotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\2PJJEOC53IN88US=> NIDGXIYyNzVxODDk MXjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MYKyNVc6PjZ{Mh?=
SKMEL1 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHnUWNtOC53IN88US=> Ml[3NU82NzhiZB?= NWG3b2hPcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M1vDeVIyPzl4NkKy
SKMEL3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6zfnhXOC53IN88US=> NUHzPXpJOS93L{ig[C=> Mn7GbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NFPaO20zOTd7Nk[yNi=>
SKMEL28 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlUh|ryP M1jUflEwPS96IHS= M{\QdYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M4n5fFIyPzl4NkKy
MeWo NUfNUHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zsZlAvPSEQvF2= M1niR|EwPS96IHS= NV\aVWdTcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NYjMd2lWOjF5OU[2NlI>
B16 M1PTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\qTlc2OC53IN88US=> MVexM|UwQCCm MoDBbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M{TEblIyPzl4NkKy
Ly 1 NGjZeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXJZY9ROjRiaB?= M3jHXWlEPTB;Nz6zJO69VQ>? NEDLd4UzOTd5MkC0PS=>
Ly 7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmyOEBp MYLJR|UxRTFyLkeg{txO MViyNVc4OjB2OR?=
Su-DHL6 NH\VZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDqSHkzPCCq M1fi[2lEPTExvK6yNEDPxE1? MUCyNVc4OjB2OR?=
Ly 10 NYmz[IN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTl[5czPCCq MWXJR|Ux97zgMkCg{txO MWmyNVc4OjB2OR?=
RIVA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PQT|I1KGh? NVvkeXZ2UUN3MP-8olIxKM7:TR?= MnSyNlE4PzJyNEm=
Su-DHL2 M3ThU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPIcocyOjRiaB?= MVLJR|Ux97zgMkCg{txO NXvqeZlpOjF5N{KwOFk>
Ly 1 NFrOc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoewOFghcA>? NYn3NHhzUUN3ME2wMlM1KM7:TR?= NHXHbGozOTd5MkC0PS=>
Ly 7 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr2OFghcA>? NWLQOVY1UUN3ME2wMlAzPSEQvF2= MViyNVc4OjB2OR?=
Su-DHL6 M3;mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPvOFghcA>? NWKxUnlOUUN3MP-8olIxKM7:TR?= M{XYXFIyPzd{MES5
Ly 10 M2DGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v5fVQ5KGh? MVXJR|UxRTFwODFOwG0> MYKyNVc4OjB2OR?=
RIVA M1j0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX5OFghcA>? NHrYV|FKSzVy78{eNlAh|ryP NGTnOIMzOTd5MkC0PS=>
Su-DHL2 M1vYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[0PEBp MYPJR|UxRTF5LkSg{txO MkDJNlE4PzJyNEm=
Ly 1 NEfQOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3TFczKGh? MmjvTWM2OD1yLkCxJO69VQ>? M32xcVIyPzd{MES5
Ly 7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp NFnaWJdKSzVyPUCuNFE5KM7:TR?= MWWyNVc4OjB2OR?=
Su-DHL6 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jKTFczKGh? NF\pUHNKSzVyPUGuOkDPxE1? M3PEdFIyPzd{MES5
Ly 10 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[3NkBp M3LHRmlEPTB;MT6yJO69VQ>? NUmzUHJWOjF5N{KwOFk>
RIVA NVvPdXVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMUJc4OiCq NXzWd4N[UUN3MP-8olIxKM7:TR?= NVXPNIlEOjF5N{KwOFk>
Su-DHL2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWyeos4OiCq M1n4cGlEPTB;MUGuNkDPxE1? MoraNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709550 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 Roswell Park Cancer Institute|National Cancer Institute (NCI) November 30 2018 Phase 1|Phase 2
NCT03691376 Not yet recruiting HLA-A*0201 Positive Cells Present|HLA-DP4 Positive Cells Present|Platinum-Resistant Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) November 25 2018 Phase 1
NCT03661307 Recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Blasts More Than 10 Percent of Bone Marrow Nucleated Cells|Blasts More Than 10 Percent of Peripheral Blood White Cells|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) October 31 2018 Phase 1|Phase 2
NCT03679650 Recruiting Acute Myelogenous Leukemia Dana-Farber Cancer Institute|National Cancer Institute (NCI) October 11 2018 Phase 1
NCT03252457 Not yet recruiting Purpura Thrombocytopenic Idiopathic|Immune Thrombocytopenia Shandong University|Second Affiliated Hospital of Medical College Shandong University|Shandong Provincial Hospital|Qingdao Central Hospital|Chinese Academy of Medical Sciences September 1 2018 Phase 3
NCT03593915 Recruiting Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID